Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients

Jinshan Shen,Robert Townsend,Xiaoli You,Yun Shen, Ping Zhan,Zexun Zhou,Dong Geng,Dianna Wu,Nadia McGirr, Kathleen Soucek,Elizabeth Proszynski,Janice Pursley,Eric Masson

Clinical Drug Investigation（2014）

引用 29|浏览5

暂无评分

摘要

Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept.

查看译文

关键词

Acute Rejection,Therapeutic Drug Monitoring,CD86 Receptor,Becton Dickinson,Belatacept

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要